MedTrace Logo

Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

NCT03317457 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2023-06-15

No results posted yet for this study

Summary

The objective of the trial is to assess the efficacy of Durvalumab and Tremelimumab in comparison to doxorubicin in treatment-naïve Soft tissue sarcoma patients

Conditions

  • Metastatic Adult Soft Tissue Sarcoma
  • Recurrent Adult Soft Tissue Sarcoma

Interventions

BIOLOGICAL

Durvalumab and Tremelimumab

immun checkpoint inhibitor

DRUG

Doxorubicin

Anthracycline

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • AIO-Studien-gGmbH

    lead OTHER

Principal Investigators

  • Viktor Grünwald, Dr. · Universitätsklinikum Essen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-15
Primary Completion
2022-08-12
Completion
2022-08-12

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03317457 on ClinicalTrials.gov